Welcome to our dedicated page for Guardant Health SEC filings (Ticker: GH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Guardant Health, Inc. (Nasdaq: GH), a precision oncology company based in Palo Alto, California. Through these filings, investors and analysts can review the company’s official disclosures about its capital structure, governance, and key events related to its blood and tissue tests, real-world data activities, and AI analytics in cancer care.
Guardant Health’s common stock is registered on The Nasdaq Global Select Market under the symbol GH, as noted in its Form 8-K filings. The company files current reports on Form 8-K to describe material events, such as public offerings of common stock, private offerings of convertible senior notes, results of stockholder meetings, financial results announcements, and board appointments. These documents outline details like underwriting agreements, convertible note terms, and voting outcomes at annual meetings.
In addition to Form 8-K reports, Guardant Health files annual reports on Form 10-K and quarterly reports on Form 10-Q, which contain more extensive information about its business, risk factors, and financial statements. Proxy statements on Schedule 14A provide further detail on governance matters and executive compensation. Together, these filings offer a regulatory record of how the company finances its operations, manages its corporate governance, and communicates significant developments to the market.
On Stock Titan, Guardant Health’s SEC filings are updated as they are made available through the EDGAR system. AI-powered tools can help summarize long documents, highlight key terms in offerings and note indentures, and make it easier to locate information on topics such as capital raises, voting results, and reporting obligations. This page is intended as a convenient starting point for reviewing Guardant Health’s regulatory disclosures in one place.
Guardant Health, Inc. director Roberto Mignone acquired 264 common shares through RSU vesting. On April 21, 2026, 264 Restricted Stock Units converted into 264 shares of common stock at a stated price of $0.00 per share, reflecting equity compensation rather than an open-market purchase or sale.
Following the transaction, Mignone directly holds 4,751 shares of common stock and 7,920 Restricted Stock Units. The RSUs come from an award granted on November 8, 2024 that vests over four years. According to the award terms, 25% of the RSUs vested on October 21, 2025, and the remaining 75% vests in equal monthly installments over the next three years.
Guardant Health director Manuel Hidalgo Medina exercised restricted stock units into common shares. On April 17, 2026, he acquired 232 shares of Guardant Health, Inc. common stock through a derivative exercise at a stated price of $0.00 per share.
Following the transaction, he directly holds 1,657 shares of common stock and 6,265 restricted stock units. The RSU award, granted on July 17, 2024, vests over four years, with 25% vesting on July 17, 2025 and the remaining 75% vesting monthly over the subsequent three years.
Guardant Health director Tariq Musa reported routine equity activity tied to a prior restricted stock unit (RSU) grant. On April 15, 2026, he exercised 250 Restricted Stock Units at $0.00, converting them into 250 shares of Common Stock. On April 16, 2026, he completed an open-market sale of 116 Common Stock shares at an average price of $84.83 per share.
Following these transactions, Musa directly holds 8,528 shares of Common Stock and 2,749 Restricted Stock Units. The RSU award, granted on March 6, 2023, vests over four years, with 25% vesting on March 15, 2024 and the remaining 75% vesting monthly over the next three years.
Guardant Health Chief Legal Officer John G. Saia reported routine equity compensation activity. On April 15, 2026, 7,569 restricted stock units converted into an equal number of Guardant Health common shares at no exercise price as part of a scheduled vesting.
Of these vested shares, 3,970 were retained by the company to satisfy Mr. Saia’s tax withholding obligations at a reference price of $84.86 per share, which is a tax-withholding disposition rather than an open-market sale. After these transactions, he directly owns 65,950 shares of Guardant Health common stock.
Guardant Health reported a Form 144 notice relating to the proposed sale of Common stock. The filing lists 9,840 Common shares with a filing date of 04/16/2026 via Charles Schwab. The excerpt also notes a restricted stock lapse on 02/15/2026 and a reported sale of 348 shares by Musa Tariq on 03/18/2026.
Guardant Health Chief People Officer sells shares in open market
Guardant Health, Inc.'s Chief People Officer, Terilyn J. Monroe, reported an open-market sale of 3,832 shares of Common Stock at $92.68 per share. After this transaction, she continues to hold 20,990 Guardant Health shares directly.
Guardant Health submitted a Form 144 disclosing proposed sales of common stock related to equity compensation and restricted stock lapses. The filing lists a Charles Schwab & Co. intermediary entry for 3,832 shares dated 04/01/2026 and two past sales by Terilyn J. Monroe of 10,031 and 8,571 shares on 01/07/2026 and 01/21/2026, respectively.
Guardant Health Chief Legal Officer John G. Saia reported routine equity compensation activity. On April 1, 2026, multiple tranches of restricted stock units vested and were exercised into a total of 11,461 shares of Common Stock at an exercise price of $0.00 per share.
To cover tax obligations related to the vesting, 6,013 Common Stock shares were retained by Guardant Health at a price of $91.15 per share, as disclosed in the footnotes. After these transactions, Saia directly held 62,351 Common Stock shares. The RSU awards were originally granted between November 2022 and March 2025 and vest over three- to four-year periods in quarterly installments.
Guardant Health, Inc. Chief People Officer Terilyn J. Monroe reported routine equity compensation activity tied to restricted stock units. On April 1, 2026, she acquired 8,019 shares of common stock upon vesting and related derivative exercises, then had 4,187 shares withheld by the company to cover tax obligations at $91.15 per share. After these transactions, she directly held 24,822 shares of common stock. The filing reflects compensation and tax withholding mechanics rather than open-market buying or selling.
Guardant Health Chief Information Officer Kumud Kalia reported routine equity compensation activity involving restricted stock units. On April 1, 2026, several restricted stock unit awards converted into a total of 10,044 shares of Common Stock, reflecting scheduled vesting from previously granted awards.
To cover related tax obligations, 5,092 Common Stock shares were withheld by Guardant Health at $91.15 per share, as described in the footnotes, and were not sold in the open market. After these transactions, Kalia directly holds 49,249 Common Stock shares, indicating an overall increase in his equity stake despite the tax withholding.